The center of the lesion is composed of cortical-type bone, sclerotic and predominantly reticular, with a large...
Understanding Your Pathology Report
Thank you for sharing this report. I can help you understand what these findings mean in educational terms. This appears to be a bone-forming tumor with specific characteristics that your pathologist has carefully documented.
Breaking Down the Key Findings
The Tumor Structure:
- The center contains cortical-type bone (dense, sclerotic bone) with atypical osteoblasts (bone-forming cells)
- The edges show immature mesenchymal cells (primitive connective tissue cells) in a collagen-rich matrix
- There are areas of cartilage differentiation with bone formation
Activity Level Markers:
- 2 mitoses/1.7 mm² — This measures cell division rate. This is a relatively LOW mitotic count, suggesting slower cell growth
- Ki67: 5% — This is a proliferation marker showing what percentage of cells are actively dividing. A 5% rate is considered LOW, indicating slower tumor growth
- Necrosis (~10%) — Areas of dead tumor tissue, which can occur in growing tumors
Immunohistochemistry Results (IHC):
- SATB2 positive in bone-forming areas — This supports the bone-forming nature of the tumor
- S100, MDM2, MUC4, p16 all negative — These negative results help rule out certain tumor types and are generally favorable findings
What This Pattern Generally Suggests
Based on these histologic features, this appears consistent with a bone-forming tumor (osteosarcoma or related lesion), though the specific diagnosis requires correlation with:
- Clinical presentation and imaging
- Patient age and location
- Your oncologist's complete assessment
According to NCCN Guidelines for bone tumors, the grade and stage of bone-forming tumors are critical for treatment planning. The relatively low mitotic rate and Ki67 index you're seeing here are important prognostic factors.
Questions to Ask Your Oncologist
Since this is a specialized pathology report, here are specific questions that will help you understand YOUR situation:
- "Based on this pathology, what is the specific diagnosis and grade of my tumor?"
- "How do the low mitotic count and Ki67 of 5% affect my prognosis and treatment options?"
- "What does the SATB2 positivity and the negative markers tell you about my tumor's behavior?"
- "What imaging studies (CT, MRI, PET) have been done, and what do they show about the extent of disease?"
- "Based on all my pathology and imaging, what treatment approach do you recommend, and why?"
Next Steps
Your oncologist will integrate this pathology with:
- Imaging findings (CT/MRI to assess local extent)
- Staging studies (chest imaging to check for metastases)
- Your clinical presentation (age, symptoms, location)
This complete picture determines your treatment plan, which may include surgery, chemotherapy, radiation, or combinations depending on your specific diagnosis and stage.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated June 1, 2026. Informational only — not a substitute for your oncology team.
Question asked:
The center of the lesion is composed of cortical-type bone, sclerotic and predominantly reticular, with a large number of atypical osteoblasts and an irregular osteoblastic rimming. At the periphery, there is a predominance of a proliferation of immature mesenchymal cells, oval in shape, with scant cytoplasm and small-to-medium-sized nuclei, relatively monotonous, with finely distributed chromatin and an inconspicuous nucleolus, set in a collagen-rich matrix with areas of keloid-like appearance. Also observed are scant foci of atypical cartilaginous differentiation with endochondral ossification. 2 mitoses/1.7 mm² are identified, and there are multiple foci of necrosis in the osteoforming component, which represent approximately 10% of the lesion. Immunohistochemical study: Positive: SATB2 in the osteoforming areas Negative: S100, MDM2, MUC4, p16 Ki67: 5%
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with clinical trials for cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about General
- A 14-year-old and has bad bone pain, could it be cancer? what should we do
- How do I know if shoulder pain is bone cancer from my follicular lymphoma
- Hi I have stage 4 bowel cancer and prostate cancer. Prostate just keep eye on bowel 10 cm mass. To large to operate...
- Cells within temporary germinal centers of lymph nodes grow without proper regulation
- What are the possible side effects of palliative radiation for metastatic prostate cancer in the bone
- Is asxl1 c.1934dup an important finding in my polycythemia vera bone marrow test
- Hi there! I have been diagnosed with ET Specifically the mutation MPL P515L it’s a blood Cancer in your Bone Marrow...
- Hi is a endoscopic procedure safe to remove the remaining cancer cells , any one else had this would love to get...